HIV cure: Toddler cured of HIV

HIV cure: Toddler cured of HIV, AIDS Advocates to Protest Gilead Sciences over HIV and Hepatitis C Drug Pricing and Policies at C.R.O.I. AIDS Healthcare Foundation (AHF), in partnership with Citywide Project Atlanta and the HCV Coalition for the Cure will convene a two-day community Drug Pricing Forum Monday, March 4 and Tuesday, March 5, 2013 on the impact of high drug prices and drug development on HIV and Hepatitis C care. Advocates from the forum will also protest Gilead Sciences’ HIV/AIDS drug pricing policies at the CROI conference outside the Georgia World Congress Center in Atlanta on both days. In September, the FDA approved Gilead’s new four-in-one AIDS treatment combination Stribild, and the drug company immediately priced Stribild at $28,500 per patient, per year, Wholesale Acquisition Cost (WAC)—a whopping 37% more than the price of Gilead’s best-selling three-in-one AIDS treatment, Atripla—and making it the most expensive combination HIV drug on the market.